Surge in US business helps boost revenue at Dechra

PET pharmaceuticals group Dechra has revealed that its revenue for the year is up by around 10% with the US being its star performer.

In a pre-close trading update for its financial year ended 30 June 2015, the group – which has a large operation in Shrewsbury – revealed that revenue from its North American operation had increased by 60% at  constant exchange rates.

Dechra said it had also seen positive momentum in Europe with revenue growth of 4%. It said this has been driven by the solid performance of its Companion Animal Products (CAP).

During the period the group saw successful launches of Levocrine, Osphos and TAF Spray and a new subsidiary in Poland started trading in May ahead of schedule.

Ian Page, chief executive officer, said: “We are pleased to report that our trading results will be ahead of last year and in line with management expectations. 

“This clearly demonstrates that we are executing our strategy successfully. We have made good progress on two aspects of our strategic plan, namely portfolio focus with good sales growth of our existing products, and geographic expansion with the opening of new subsidiaries. 

“We remain well placed for future growth.”

Close